{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:31:35Z","timestamp":1787923895529,"version":"build-2784847793"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007471","name":"Northern Borders University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statin therapy is frequently associated with concerns regarding creatine kinase (CK) elevation and potential muscle toxicity. Although clinically significant statin-associated muscle injury is uncommon, the interpretation of routine CK variability during outpatient statin therapy remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate CK variability among outpatient statin users and identify patient-and treatment-related factors associated with CK levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cross-sectional study was conducted among adult outpatient attending cardiology, endocrinology, or internal medicine clinics at a tertiary care center in Saudi Arabia between January-2020 to December-2021. Demographic characteristics, comorbidities, statin exposure, statin intensity, concomitant medications, renal function, and laboratory parameters were extracted from electronic medical records. Multivariable linear regression analyses were performed to identify factors independently associated with CK levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 6,517 patients were included, of whom 3,223 (49.5%) received statin therapy. Statin users had higher CK levels than non-users (112 vs. 80 IU\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). CK values were generally distributed within a narrow range, with a median of 94 IU\/L (IQR 68\u2013121) and 95% of measurements below 157 IU\/L. In the fully adjusted model, statin use (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u200931.84, 95% CI 29.98\u201333.69;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) and male sex (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u200913.95, 95% CI 12.36\u201315.53;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) were independently associated with higher CK levels. Thyroid disorder demonstrated a modest association with CK levels (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u20092.60, 95% CI 0.32\u20134.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statin use and male sex were the primary factors associated with CK variability in this outpatient population. Despite modestly higher CK concentrations among statin users, most measurements remained within a relatively narrow range, and no dose-response relationship was observed according to statin intensity or statin type. These findings provide real-world evidence to support the interpretation of routine CK measurements during outpatient statin therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1903467","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:53:13Z","timestamp":1787921593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with creatine kinase variability among statin users in routine outpatient care: a retrospective cross-sectional study"],"prefix":"10.3389","volume":"13","author":[{"given":"Aymen","family":"Alqurain","sequence":"first","affiliation":[{"name":"Department of Clinical Practice, Faculty of Pharmacy, Northern Border University","place":["Rafha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Alsultan","sequence":"additional","affiliation":[{"name":"Al-Dawaa Medical Services Company","place":["Alhafouf, Eastern Province Alhassa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam K.","family":"Alamoudi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University","place":["Al-Kharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Almohaywi","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Shakoori","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University","place":["Makkah, Kingdome of Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al Gharash","sequence":"additional","affiliation":[{"name":"Emergency and Intensive Care Department, College of Nursing, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Alsaffar","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani S.","family":"Alrossies","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.24911\/IJMDC.51-1685365843","article-title":"Lipid lowering agent prescription and LDL target achievement in ACS patients in Jeddah, Saudi Arabia","volume":"10","author":"Almaramihi","year":"2023","journal-title":"Threshold"},{"key":"B2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2174\/18756417MTA2kOTQCw","article-title":"Cardiovascular disease among patients with diabetes: the current scenario in Saudi Arabia","volume":"17","author":"Robert","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/clc.22577","article-title":"Prevalence and factors associated with statin use among a nationally representative sample of US adults: national health and nutrition examination survey, 2011\u20132012","volume":"39","author":"Adedinsewo","year":"2016","journal-title":"Clin Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the national lipid association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"103304","DOI":"10.1016\/j.amsu.2022.103304","article-title":"Statin induced myopathy among patients attending the national center for diabetes, endocrinology, & genetics","volume":"74","author":"Abed","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e23463","DOI":"10.7759\/cureus.23463","article-title":"Prevalence of self-reported muscle pain among statin users from national guard hospital, Riyadh","volume":"14","author":"Suliman","year":"2022","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104201","DOI":"10.1016\/j.phrs.2019.03.010","article-title":"Mechanisms of statin-associated skeletal muscle-associated symptoms","volume":"154","author":"Bouitbir","year":"2020","journal-title":"Pharmacol Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm9010022","article-title":"Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components","volume":"9","author":"Turner","year":"2019","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"575678","DOI":"10.3389\/fgene.2020.575678","article-title":"Pharmacogenetics of statin-induced myotoxicity","volume":"11","author":"Kee","year":"2020","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"Du Souich","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"B12","first-page":"20","article-title":"Pattern of statin use in patients with diabetes mellitus type 2 for primary and secondary prevention of cardiovascular disease in Saudi Arabia","volume":"28","author":"Ismail","year":"2020","journal-title":"Afr J Diabetes Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1183\/09031936.00059814","article-title":"Ageing and the epidemiology of multimorbidity","volume":"44","author":"Divo","year":"2014","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B15","article-title":"Anatomical Therapeutic Chemical (ATC) Classification index with Defined Daily Doses (DDDs)","volume-title":"Methodology CCfDS","year":"2000"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jclinepi.2010.02.015","article-title":"Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting","volume":"64","author":"Lu","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B19","volume-title":"International Statistical Classification of Disease and Related Health Problems 10th Revision (ICD-10)-wHO Version for 2016","year":"2016"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1357171","DOI":"10.3389\/fphar.2024.1357171","article-title":"The prevalence of polypharmacy and hyper-polypharmacy among middle-aged vs. older patients in Saudi Arabia: a cross-sectional study","volume":"15","author":"Alqurain","year":"2024","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the international lipid expert panel (ILEP)","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e000275","DOI":"10.1136\/bmjdrc-2016-000275","article-title":"Evaluation of statin prescriptions in type 2 diabetes: India heart watch-2","volume":"4","author":"Gupta","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-019-4423-9","article-title":"Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia","volume":"12","author":"Demoz","year":"2019","journal-title":"BMC Res Notes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e014742","DOI":"10.1161\/JAHA.119.014742","article-title":"Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis","volume":"9","author":"Zhao","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B27","first-page":"617","article-title":"Prevalence of statin induced myopathy in Lahore, Pakistan","volume":"31","author":"Sadeeqa","year":"2018","journal-title":"Pak J Pharm Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40266-019-00742-0","article-title":"Prevalence and factors associated with analgesic prescribing in poly-medicated elderly patients","volume":"37","author":"Al-Qurain","year":"2020","journal-title":"Drugs Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ahj.2007.06.008","article-title":"Distribution of creatine kinase in the general population: implications for statin therapy","volume":"154","author":"Brewster","year":"2007","journal-title":"Am Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/07435800500371706","article-title":"Serum creatine kinase levels in overt and subclinical hypothyroidism","volume":"31","author":"Hekimsoy","year":"2005","journal-title":"Endocr Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e40080","DOI":"10.1097\/MD.0000000000040080","article-title":"Reversible elevation of creatine kinase and creatinine caused by sintilimab-induced hypothyroidism: a case report","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","article-title":"Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)","volume":"34","author":"Fulster","year":"2013","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2337\/db05-1183","article-title":"Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/bmb\/ldm014","article-title":"Creatine kinase monitoring in sport medicine","volume":"81","author":"Brancaccio","year":"2007","journal-title":"Br Med Bull"},{"key":"B37","doi-asserted-by":"publisher","first-page":"960363","DOI":"10.1155\/2012\/960363","article-title":"Creatine-kinase-and exercise-related muscle damage implications for muscle performance and recovery","volume":"2012","author":"Baird","year":"2012","journal-title":"J Nutr Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1903467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:53:14Z","timestamp":1787921594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1903467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2026.1903467"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1903467","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1903467"}}